Determining The Role Of Vitamin D In The Development Of Asthma And Allergic Diseases In High Risk Families
Funder
National Health and Medical Research Council
Funding Amount
$351,127.00
Summary
Allergic diseases like asthma, eczema and hay-fever, prevent our children from getting a healthy start to life, and we don’t know how to prevent these conditions. Vitamin D levels may be critical in the development of childhood asthma and allergies, and they can be easily modified! Using a group of 620 children who we have followed for 20 years, we will identify the role of vitamin D levels in the development of allergic conditions, and factors that modify these relationships.
A Population-based Family Study Of Filaggrin Mutations And Allergic Disease Risk In Australia
Funder
National Health and Medical Research Council
Funding Amount
$308,584.00
Summary
It is biologically plausible that the association of known environmental risk factors for asthma may be different for genetically susceptible individuals. Few studies have examined the interaction between genetic and environmental factors. that have not considered genetic susceptibility are estimating an average risk of asthma across all genotypes in the population which may not be relevant for a particular sub-group.
Epidemiology Of Allergic Diseases And The Role Of Early Life Eczema
Funder
National Health and Medical Research Council
Funding Amount
$416,306.00
Summary
Eczema prevents our children from getting a healthy start to life, increases their risk of developing asthma and hay-fever, and we don’t know how to prevent this condition. Dr. Lowe will help identify causes and the outcomes of eczema and allergic diseases in early life, by using a number of important research projects. This research includes an intervention trial that aims to prevent the development of allergic disease and sensitisation, which Dr Lowe leads
Allergies and chronic respiratory diseases are major causes of illness and death in Australia. Worryingly there are still many gaps in knowledge on how best to prevent and manage these diseases. The proposed program will investigate these questions and provide evidence to guide health policy and clinical management. As this program is built on state-of the-art methods and technology, these original Australian findings will be of great importance internationally.
MULTICENTRE BRONCHIECTASIS STUDY: A Collaborative And International Study Of Bronchiectasis In Indigenous Children.
Funder
National Health and Medical Research Council
Funding Amount
$1,496,414.00
Summary
Aboriginal children have repeated pneumonia episodes; some get better while others develop bronchiectasis (a chronic lung disease). The risk factors associated with progression to bronchiectasis, and the natural history of bronchiectasis in this population is little known. Given the similarities of these diseases among indigenous populations of affluent countries and to increase study size, a collaborative and international study of Indigenous children (Aboriginal and Torres Strait Islander, New ....Aboriginal children have repeated pneumonia episodes; some get better while others develop bronchiectasis (a chronic lung disease). The risk factors associated with progression to bronchiectasis, and the natural history of bronchiectasis in this population is little known. Given the similarities of these diseases among indigenous populations of affluent countries and to increase study size, a collaborative and international study of Indigenous children (Aboriginal and Torres Strait Islander, New Zealand Maori or Pacific Islander and Alaskan Native) has been initiated. In Indigenous children, we aim to define the natural history of chronic moist cough (those at risk of developing bronchiectasis) and bronchiectasis, identify the risk factors associated with progression from early-mild disease (chronic moist cough) to bronchiectasis and to define the role of continuous antibiotic treatment in the prevention of recurrent pulmonary infections that are very common in these children. We plan to follow up Aboriginal children aged 12 months to 8 years diagnosed with bronchiectasis or chronic moist cough. For those diagnosed with bronchiectasis, after fully informed consent is obtained from the parent(s), the child will be allocated by chance to one of the 2 treatment regimes: (1) Azithromycin once-week or (2) placebo once-week. Children will receive the medication or the placebo for a period of 24 months. All these children will be clinically seen 2x-year by the study's paediatrician and 2x-year by the research nurse for the duration of the study. By documenting, for the first time, the epidemiology and natural history of children with chronic moist cough and bronchiectasis, the study will provide a much-needed rationale for their management. If we can scientifically show that this is true, that Azithromycin is effective in reducing the number of respiratory infections, this would be an achievable advance in the treatment in the field for these children.Read moreRead less